Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by fossi_2002on Feb 21, 2024 9:28am
125 Views
Post# 35890585

There has been a complete loss of confidence here

There has been a complete loss of confidence hereSometimes it's just hard to bear when you read the cheese that Proph is spouting.

How can you judge the performance of a company or its leader?
Obviously, only on the basis of past performance.

What are these achievements?
The basic business was never developed further, new products were overslept and the sales side was completely neglected.
First a sales manager was hired
, then Gilles took over this side again himself. The result is well known. From high profits into the red.

Proph repeatedly praises the cooperation between CZO and Symrise.
An agreement that was praised by many parties turned out to be empty chatter in retrospect.
In contrast to the hymns of praise, one has the feeling that Symrise has stabbed Ceapro in the back with its own development.

And then there is the development of the biotech business. Success rate since the beginning: 0
Of course, development in the biotech sector takes many years. Gilles has proven one thing: he has no foresight.
How long did Proph ignore the failure of the cholesterol-lowering drug and claim that something could still be developed?
How long has the failure of the energy drink been repeatedly referred to as "no failure".
How many delays and failures to meet deadlines and developments did we have to put up with!

Can the loss in value of a share like AEZS be higher?
And now this management wants to demand a further leap of faith from the shareholders.
We are led to believe that AEZS has an enormously high cash position.

However, this is only half the truth.I
n the report on the third quarter, everyone can read that the cash on hand is sufficient for the further development of AEZS's current pipeline until the end of 2025.
How is this cash balance supposed to be sufficient to further develop the pipeline of CZO and PGX in particular?
This is not possible at all under these circumstances.

It is therefore clear that a significant capital increase and thus a further dilution of the shares will and must take place after another reverse stock split.
AEZS is not the solution. Neither in the presentations nor in the individual quarterly reports is there a solution as to how the monthly cash drain can be stopped.
Quarterly losses
of over $4m indicate how long the cash position will last.

Biotech stocks were not the stock market's favorite for some time. Nevertheless, the biotech index has developed positively in recent months, reaching its high for the year.
Have the shareholders of CZO and AEZS noticed any of this? NO!

There has been a complete loss of confidence here and this can only be made good if Gilles Gagnon takes his hat off!!!






<< Previous
Bullboard Posts
Next >>